Gene Therapy Company Emendo Biotherapeutics Raises $61 Million

Emendo uses protein engineering to treat certain genetic disorders and diseases

Adi Pick 11:3716.01.20
New York-based gene therapy company Emendo Biotherapeutics Inc. has raised a $61 million series B funding round, the company announced Wednesday. The round was led by Tokyo-listed pharmaceutical company AnGes Inc.


Founded in 2015 by alumni of Israel's Weizmann Institute of Science Lior Izhar, David Baram, and Rachel Diamant, Emendo utilizes protein engineering for precision gene editing, altering single alleles to treat certain genetic disorders and diseases. The company has raised $73 million to date, according to Pitchbook data.

Protein engineering (illustration). Photo: Pixabay Protein engineering (illustration). Photo: Pixabay